GlassScriptPhysician profile
Lacey H Case
NPI 1689113540
$1,317.75
in general payments reported to CMS, 2019-2025
12 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $305 · 2023: $24.48 · 2024: $426 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $376.73 | 2021-2024 | Micra |
| Stryker Corporation | $180.27 | 2025 | Flowtriever, Clottriever Bold Catheter, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $177.58 | 2021-2025 | Wainua |
| Novartis Pharmaceuticals Corporation | $138.19 | 2024 | |
| Alnylam Pharmaceuticals INC. | $122.93 | 2025 | Amvuttra |
| Abiomed | $81.93 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.20 | 2021-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $70.73 | 2022 | |
| Amgen INC. | $43.40 | 2023-2024 | Repatha |
| Amarin Pharma, INC. | $24.05 | 2021 | |
| Chiesi USA, INC. | $15.04 | 2025 | Kengreal |
| Daiichi Sankyo INC. | $14.70 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.